Opioids

Five things for pharma marketers to know: Thursday, October 20, 2016

Five things for pharma marketers to know: Thursday, October 20, 2016

By

Chicago to require pharma reps to track their calls; GlaxoSmithKline joins Instagram; Lilly receives accelerated approval for cancer drug

Five things for pharma marketers to know: Monday, May 16, 2016

Five things for pharma marketers to know: Monday, May 16, 2016

By

Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill

Five things for pharma marketers to know: Friday, May 6, 2016

Five things for pharma marketers to know: Friday, May 6, 2016

By

Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee

Five things for pharma marketers to know: Thursday, May 5, 2016

Five things for pharma marketers to know: Thursday, May 5, 2016

By

U.S. Keytruda sales miss mark; the CDC warns parents to try therapy before drugs for children with ADHD; FDA panel recommends training for opioid prescribers

Five things for pharma marketers to know: Thursday, September 10, 2015

Five things for pharma marketers to know: Thursday, September 10, 2015

By

Cardiologists say that up to 15% of their patients could be on PCSK9 inhibitors next year; FDA committee to evaluate new Oxycodone version

Five things for pharma marketers to know: Thursday, March 26

Five things for pharma marketers to know: Thursday, March 26

By

Regeneron's Eylea won its fourth indication; Sun Pharma wants to revive trust in its products; confidentiality agreements keep Amgen from telling patients their cancer risk

Five things for pharma marketers to know: Monday, February 2

Five things for pharma marketers to know: Monday, February 2

By By

Pfizer ends spinal muscular atrophy collaboration; abuse-deterrent Zohydro scores approval; measles outbreak at Disneyland linked to 36 cases.

OPINION

Email Newsletters